Keywords
SARS CoV-2
MSC Therapy
ACE-2
How to Cite
Abstract
The Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) outbreak, also known as COVID-19, from the seafood market in Wuhan, China, has the world on its knees within a short time, impacting health infrastructure, economy, science, and most importantly human existence. On March 11, 2020, the World Health Organization (WHO) declared COVID-19 a pandemic. Since the first encounter with COVID-19, the medical fraternity has been exploring various ways to counter the disease and related complications. Attempts have also been made to prevent infection by developing vaccines to reduce the severity of the disease and mortality postinfection. However, even as the first peak of the epidemic (also known as the “first wave”) has flattened, the second peak (second wave) has been even more detrimental, with a rapid rise leading to an unprecedented burden on healthcare infrastructure and resulting in high mortality. The second wave has been predicted to be triggered by a double mutant strain, which resulted in a higher incidence of pneumonia, faster progression of the disease, increased oxygen requirements, and higher mortality. In contrast to the current treatment options available, which include antivirals, antimalarial, and anti-inflammatory agents, MSC can be proved to be a better treatment modality for COVID-19. In this article, we focus on the role and use of mesenchymal stem cells (MSC) as a potential therapeutic measure to win the battle against the SARS-CoV-2 virus.
References
Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID‐19 based on current evidence. Journal of medical virology. 2020 Jun;92(6):548-51. https://doi.org/10.1002/jmv.25722
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. nature. 2020 Mar;579(7798):270-3. https://doi.org/10.1038/s41586-020-2012-7
Fara A, Mitrev Z, Rosalia RA, Assas BM. Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. Open biology. 2020 Sep 23;10(9):200160. https://doi.org/10.1098/rsob.200160
Chen X, Shan Y, Wen Y, Sun J, Du H. Mesenchymal stem cell therapy in severe COVID-19: A retrospective study of short-term treatment efficacy and side effects. Journal of Infection. 2020 Oct 1;81(4):647-79. https://doi.org/10.1016%2Fj.jinf.2020.05.020
Lu L, Van Dung N, Ivens A, Bogaardt C, O’Toole A, et al. Genetic diversity and cross-species transmission of kobuviruses in Vietnam. Virus evolution. 2018 Jan;4(1):vey002. https://doi.org/10.1093/ve/vey002
Abduljalil JM, Abduljalil BM. Epidemiology, genome, and clinical features of the pandemic SARS-CoV-2: a recent view. New microbes and new infections. 2020 May 1;35:100672.
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The lancet. 2020 Feb 22;395(10224):565-74. https://doi.org/10.1016/S0140-6736(20)30251-8
Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005 Sep 16;309(5742):1864-8. https://doi.org/10.1126/science.1116480
Peng Y, Du N, Lei Y, Dorje S, Qi J, Luo T, et al. Structures of the SARS‐CoV‐2 nucleocapsid and their perspectives for drug design. The EMBO journal. 2020 Oct 15;39(20):e105938. https://doi.org/10.15252/embj.2020105938
Devaux CA, Rolain JM, Raoult D. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. Journal of Microbiology, Immunology and Infection. 2020 Jun 1;53(3):425-35. https://doi.org/10.1016/j.jmii.2020.04.015
Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nature medicine. 2020 Apr;26(4):450-2. https://doi.org/10.1038/s41591-020-0820-9
Han Y, Li X, Zhang Y, Han Y, Chang F, Ding J. Mesenchymal stem cells for regenerative medicine. Cells. 2019 Aug 13;8(8):886. https://doi.org/10.3390/cells8080886
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. cell. 2020 Apr 16;181(2):271-80. https://doi.org/10.1016/j.cell.2020.02.052
Su S, Shao Y, Jiang S. Human challenge trials to assess the efficacy of currently approved COVID-19 vaccines against SARS-CoV-2 variants. Emerging Microbes & Infections. 2021 Jan 1;10(1):439-41. https://doi.org/10.1080/22221751.2021.1896956
Tang L, Jiang Y, Zhu M, Chen L, Zhou X, Zhou C, et al. Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19. Frontiers of medicine. 2020 Oct;14(5):664-73. https://doi.org/10.1007/s11684-020-0810-9
Rajarshi K, Chatterjee A, Ray S. Combating COVID-19 with mesenchymal stem cell therapy. Biotechnology reports. 2020 Jun 1;26:e00467. https://doi.org/10.1016/j.btre.2020.e00467
COVID M. lung vessels obstructive thrombo inflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Text (visual): unmediated//Crit Care Resusc.–2020.
McGonagle D, Sharif K, O'Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmunity reviews. 2020 Jun 1;19(6):102537. https://doi.org/10.1016/j.autrev.2020.102537
Iyer SS, Co C, Rojas M. Mesenchymal stem cells and inflammatory lung diseases. Panminerva Med. 2009 Mar 1;51(1):5-16. Available at: https://usstemology.com/wp-content/uploads/2019/05/Mesenchymal-stem-cells-and-inflammatory-lung-diseases.pdf
Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial. Annals of internal medicine. 2020 Oct 20;173(8):623-31. https://doi.org/10.7326/M20-4207
Sánchez-Guijo F, García-Arranz M, López-Parra M, Monedero P, Mata-Martínez C, Santos A, et al. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. EClinicalMedicine. 2020 Aug 1;25:100454. https://doi.org/10.1016/j.eclinm.2020.100454
Liang B, Chen J, Li T, Wu H, Yang W, Li Y, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report. Medicine. 2020 Jul 7;99(31). https://doi.org/10.1097/MD.0000000000021429
Zhang Y, Ding J, Ren S, Wang W, Yang Y, Li S, et al. Intravenous infusion of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia. Stem cell research & therapy. 2020 Dec;11(1):1-6. Available from: http://dx.doi.org/10.1186/s13287-020-01725-4
Tao J, Nie Y, Wu H, Cheng L, Qiu Y, Fu J, et al. Umbilical cord blood-derived mesenchymal stem cells in treating a critically ill COVID-19 patient. Journal of Infection in Developing Countries. 2020 Oct 1;14(10). https://doi.org/10.3855/jidc.13081
Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging and disease. 2020 Apr;11(2):216. https://doi.org/10.14336/AD.2020.0228
Hashemian SM, Aliannejad R, Zarrabi M, Soleimani M, Vosough M, Hosseini SE, et al. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Stem cell research & therapy. 2021 Dec;12(1):1-2. https://doi.org/10.1186/s13287-021-02165-4
Chen J, Hu C, Chen L, Tang L, Zhu Y, Xu X, et al. Clinical study of mesenchymal stem cell treatment for acute respiratory distress syndrome induced by epidemic influenza A (H7N9) infection: a hint for COVID-19 treatment. Engineering. 2020 Oct 1;6(10):1153-61. https://doi.org/10.1016/j.eng.2020.02.006
Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N. Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem cells and development. 2020 Jun 15;29(12):747-54. https://doi.org/10.1089/scd.2020.0080
Yu B, Ikhlas S, Ruan C, Zhong X, Cai D. Innate and adaptive immunity of murine neural stem cell-derived piRNA exosomes/microvesicles against pseudotyped SARS-CoV-2 and HIV-based lentivirus. IScience. 2020 Dec 18;23(12):101806. https://doi.org/10.1016/j.isci.2020.101806
Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: Their roles in pathogenesis. Journal of Microbiology, Immunology and Infection. 2021 Apr 1;54(2):159-63. https://doi.org/10.1016/j.jmii.2020.03.022
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. New England Journal of Medicine. 2020 Mar 18. https://doi.org/10.1056/NEJMoa2001282
Bolarin JA, Oluwatoyosi MA, Orege JI, Ayeni EA, Ibrahim YA, Adeyemi SB, et al. Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective. International Immunopharmacology. 2021 Jan 1;90:107228. https://doi.org/10.1016/j.intimp.2020.107228
Zhang Y, Zhong Y, Pan L, Dong J. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?. Drug discoveries & therapeutics. 2020 Apr 30;14(2):100-2. https://doi.org/10.5582/ddt.2020.03006
Saiz-Rodríguez M, Peña T, Lázaro L, González Á, Martínez A, Cordero JA, et al. Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: a structured summary of a randomised controlled trial. Trials. 2020 Dec;21(1):1-3. https://doi.org/10.1186/s13063-020-04575-w
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral research. 2020 Jun 1;178:104787. https://doi.org/10.1016/j.antiviral.2020.104787
Harvala H, Robb ML, Watkins N, Ijaz S, Dicks S, Patel M, et al. Convalescent plasma therapy for the treatment of patients with COVID‐19: assessment of methods available for antibody detection and their correlation with neutralising antibody levels. Transfusion Medicine. 2021 Jun;31(3):167-75. https://doi.org/10.1111/tme.12746
He Q, Mao Q, An C, Zhang J, Gao F, Bian L, et al. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerging microbes & infections. 2021 Jan 1;10(1):629-37. https://doi.org/10.1080/22221751.2021.1902245
Su S, Shao Y, Jiang S. Human challenge trials to assess the efficacy of currently approved COVID-19 vaccines against SARS-CoV-2 variants. Emerging Microbes & Infections. 2021 Jan 1;10(1):439-41. https://doi.org/10.1080/22221751.2021.1896956
Wong JP, Viswanathan S, Wang M, Sun LQ, Clark GC, D'elia RV. Current and future developments in the treatment of virus-induced hypercytokinemia. Future medicinal chemistry. 2017 Feb;9(2):169-78. https://doi.org/10.7150/ijbs.59534
Canham MA, Campbell JD, Mountford JC. The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019. Journal of Translational Medicine. 2020Dec;18(1):1-5. https://doi.org/10.1186/s12967-020-02532-4
Zheng G, Huang L, Tong H, Shu Q, Hu Y, Ge M, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respiratory research. 2014 Dec;15(1):1-0. https://doi.org/10.1186/1465-9921-15-39
Chan MC, Kuok DI, Leung CY, Hui KP, Valkenburg SA, Lau EH, et al. Human mesenchymal stromal cells reduce influenza A H5N1-associated acute lung injury in vitro and in vivo. Proceedings of the National Academy of Sciences. 2016 Mar 29;113(13):3621-6. https://doi.org/10.1073/pnas.1601911113
Loy H, Kuok DI, Hui KP, Choi MH, Yuen W, Nicholls JM, et al. Therapeutic implications of human umbilical cord mesenchymal stromal cells in attenuating influenza A (H5N1) virus–associated acute lung injury. The Journal of infectious diseases. 2019 Jan 7;219(2):186-96. https://doi.org/10.1093/infdis/jiy478
Durand N, Mallea J, Zubair AC. Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure. npj Regenerative Medicine. 2020 Oct 26;5(1):1-9. https://doi.org/10.1038/s41536-020-00105-z
Schluger NW. The saga of hydroxychloroquine and COVID-19: A cautionary tale. Annals of Internal Medicine. 2020 Oct 20;173(8):662-3. https://doi.org/10.7326/M20-5041